$ZBH

Phipps Chad F sold $295K of ZBH

Phipps Chad F (See remarks below.) sold 3,000 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $98.35 ($0.30M total) on 2026-09-04.

Original reporting
SEC EDGAR · Phipps Chad F
Published Sep 9, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ZBH
Neutral
low confidence
Mentioned
$ZBH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZBHNeutralLow
01

Why it matters

Traders may note insider selling as a sentiment datapoint, but there is no accompanying company-specific catalyst (earnings, guidance, deal, or enforcement).

02

Market read

A modest officer open-market sale is unlikely to drive a durable repricing without other fundamental news.

03

What to watch

The filing does not indicate a 10b5-1 plan, but it also provides no context on motivation, option exercises, or compensation timing.

Relevance 4/10Novelty 2/10Timing: filed 2026-09-09 after-hours; transaction dated 2026-09-04

Background

The article is an SEC Form 4 insider transaction disclosure for Zimmer Biomet Holdings, Inc.

Company-level read

Ticker impact

$ZBHNeutralLow confidence
Context

SEC Form 4 shows officer Phipps Chad F sold 3,000 ZBH shares at $98.3500 on 2026-09-04 for about $295,050.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The transaction is modest in dollar terms and is an open-market sale by an officer, not a buy, guidance change, or regulatory/legal event.

Market effects

No clear sector read-through from a single, modest insider sale.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, so the signal may be overstated.

Key entities

  • Zimmer Biomet Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Phipps Chad F

    Officer who sold 3,000 shares of ZBH on 2026-09-04.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZBHMed

Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

Zimmer Biomet (ZBH) reported Q2 results on Aug. 5, with adjusted EPS of $2.07 vs $2.01 expected and revenue of $2.2B vs $2.1B forecast. The company guided full-year adjusted EPS to $8.47-$8.59. Analysts covering ZBH have a Hold consensus, with a mean price target of $104.67 and a Street-high of $125.

$ZBHMedAI 8/10

Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary

Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.

$ZBHHighAI 9/10

ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market

Zimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.